2Schiano P,Gabriel Steg P.Measurement and prevention of myocardial injury during percutaneous coronary intervention.Heart,2007,93:656-657.
3Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
4Lavanchy N,Martin J,Rossi A.Anti-ischemic effects of trimetazidine:31P-NMR spectroscopy in the isolated rat heart.Arch Int Pharmacodyn Ther,1987,286:97-110.
5Renaud JF.Internal pH,Na +,and Ca2 + regulation by trimetazidine during cardiac cell acidosis.Cardiovasc Drugs Ther,1988,1:677-686.
6Cuamieri C,Muscari C.Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium.Pharmacology,1993,46:324-331.
7Boucher FR,Hearse DJ,Opie LH.Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts.J Cardiovasc Pharmacol,1994,24:45-49.
8Belcher PR,Drake-Holland AJ,Hynd JW,et al.Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.Cardiovasc Drugs Ther,1993,7:149-157.
9Williams FM,Tanda K,Kus M,et al.Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits.J Cardiovasc Pharmacol,1993,22:828-833.
10Kantor PF,Lucien A,Kozak R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme A thiolase.Circ Res,2000,86:580-588.
